Michael R Holbrook

List of Publications by Year
in descending order

109 papers	5,795 citations	70961 41 h-index	88477 70 g-index
122 all docs	122 docs citations	122 times ranked	8557 citing authors

#	Article	IF	Citations
1	Expanded Histopathology and Tropism of Ebola Virus in the Rhesus Macaque Model. American Journal of Pathology, 2022, 192, 121-129.	1.9	9
2	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117
3	Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell, 2022, 185, 995-1007.e18.	13.5	26
4	T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity. JCI Insight, 2022, 7, .	2.3	26
5	Clinical grade <scp>ACE2</scp> as a universal agent to block <scp>SARSâ€CoV</scp> â€2 variants. EMBO Molecular Medicine, 2022, 14, .	3.3	35
6	Broadly neutralizing antibodies target the coronavirus fusion peptide. Science, 2022, 377, 728-735.	6.0	111
7	Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. Journal of Clinical Investigation, 2021, 131, .	3.9	72
8	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. Microorganisms, 2021, 9, 566.	1.6	13
9	Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples. Viruses, 2021, 13, 893.	1.5	21
10	Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection. Journal of Infectious Diseases, 2021, 224, 1294-1304.	1.9	52
11	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj5413.	5.8	79
12	<i>How do I</i>â€¦ facilitate a rapid response to a public health emergency requiring plasma collection with a publicâ€“private partnership?. Transfusion, 2021, 61, 2814-2824.	0.8	2
13	COVID-19 Antibody Detection and Assay Performance Using Red Cell Agglutination. Microbiology Spectrum, 2021, 9, e0083021.	1.2	3
14	The Use of Large-Particle Aerosol Exposure to Nipah Virus to Mimic Human Neurological Disease Manifestations in the African Green Monkey. Journal of Infectious Diseases, 2020, 221, S419-S430.	1.9	11
15	Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig. Antiviral Research, 2020, 181, 104863.	1.9	16
16	Repurposing PyramaxÂ®, quinacrine and tilorone as treatments for Ebola virus disease. Antiviral Research, 2020, 182, 104908.	1.9	20
17	The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30687-30698.	3.3	22
18	Peripheral immune response in the African green monkey model following Nipah-Malaysia virus exposure by intermediate-size particle aerosol. PLoS Neglected Tropical Diseases, 2019, 13, e0007454.	1.3	18

#	Article	IF	Citations
19	Neurotropic Viruses. , 2019, , 1-20.		1
20	Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samples. PLoS ONE, 2019, 14, e0221407.	1.1	11
21	In Vivo Activity of Amodiaquine against Ebola Virus Infection. Scientific Reports, 2019, 9, 20199.	1.6	16
22	Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease. American Journal of Pathology, 2018, 188, 550-558.	1.9	33
23	The Human Sodium Iodide Symporter as a Reporter Gene for Studying Middle East Respiratory Syndrome Coronavirus Pathogenesis. MSphere, 2018, 3, .	1.3	8
24	Aerosol exposure to intermediate size Nipah virus particles induces neurological disease in African green monkeys. PLoS Neglected Tropical Diseases, 2018, 12, e0006978.	1.3	26
25	Kyasanur Forest disease virus infection activates human vascular endothelial cells and monocyte-derived dendritic cells. Emerging Microbes and Infections, 2018, 7, 1-12.	3.0	10
26	The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease. Journal of Infectious Diseases, 2018, 218, S588-S591.	1.9	28
27	Will a Single-Cycle Adenovirus Vaccine Be Effective Against Ebola Virus?. Journal of Infectious Diseases, 2018, 218, 1858-1860.	1.9	0
28	Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. Journal of Infectious Diseases, 2018, 218, S672-S678.	1.9	49
29	Development of a novel real-time polymerase chain reaction assay for the quantitative detection of Nipah virus replicative viral RNA. PLoS ONE, 2018, 13, e0199534.	1.1	25
30	Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. PLoS ONE, 2018, 13, e0194880.	1.1	31
31	MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS ONE, 2018, 13, e0194868.	1.1	93
32	Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection. Npj Vaccines, 2017, 2, 5.	2.9	36
33	A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. Npj Vaccines, 2017, 2, 21.	2.9	54
34	Historical Perspectives on Flavivirus Research. Viruses, 2017, 9, 97.	1.5	129
35	Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus. PLoS Neglected Tropical Diseases, 2017, 11, e0005532.	1.3	36
36	Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. PLoS ONE, 2016, 11, e0166318.	1.1	28

#	Article	IF	Citations
37	Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 2. General Practices. Journal of Visualized Experiments, 2016, , .	0.2	6
38	Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 1. Biosafety Level 4 Suit Laboratory Suite Entry and Exit Procedures. Journal of Visualized Experiments, 2016, , .	0.2	16
39	Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 4. Medical Imaging Procedures. Journal of Visualized Experiments, 2016, , .	0.2	6
40	Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 3. Aerobiology. Journal of Visualized Experiments, 2016, , .	0.2	6
41	3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology, 2016, 490, 49-58.	1.1	67
42	Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Science Translational Medicine, 2016, 8, 326ra21.	5.8	102
43	Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells. PLoS Neglected Tropical Diseases, 2016, 10, e0004709.	1.3	29
44	Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus. Journal of Virological Methods, 2015, 223, 13-18.	1.0	75
45	Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology, 2015, 485, 422-430.	1.1	47
46	Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy, 2015, 59, 1088-1099.	1.4	344
47	Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus. Journal of General Virology, 2015, 96, 1651-1663.	1.3	13
48	Comparative Pathogenesis of Alkhumra Hemorrhagic Fever and Kyasanur Forest Disease Viruses in a Mouse Model. PLoS Neglected Tropical Diseases, 2014, 8, e2934.	1.3	24
49	A Critical Determinant of Neurological Disease Associated with Highly Pathogenic Tick-Borne Flavivirus in Mice. Journal of Virology, 2014, 88, 5406-5420.	1.5	28
50	Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 4885-4893.	1.4	564
51	Animal models of viral hemorrhagic fever. Antiviral Research, 2014, 112, 59-79.	1.9	42
52	Interferon-Î² and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. Journal of General Virology, 2014, 95, 571-577.	1.3	191
53	Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes. Virus Research, 2013, 175, 155-159.	1.1	14
54	Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine. PLoS Pathogens, 2013, 9, e1003389.	2.1	106

#	Article	IF	Citations
55	Chemotactic and Inflammatory Responses in the Liver and Brain Are Associated with Pathogenesis of Rift Valley Fever Virus Infection in the Mouse. PLoS Neglected Tropical Diseases, 2012, 6, e1529.	1.3	46
56	Kyasanur forest disease. Antiviral Research, 2012, 96, 353-362.	1.9	101
57	An Assembly Model of Rift Valley Fever Virus. Frontiers in Microbiology, 2012, 3, 254.	1.5	32
58	Release of Dengue Virus Genome Induced by a Peptide Inhibitor. PLoS ONE, 2012, 7, e50995.	1.1	71
59	Construction of an infectious cDNA clone for Omsk hemorrhagic fever virus, and characterization of mutations in NS2A and NS5. Virus Research, 2011, 155, 61-68.	1.1	25
60	Tick-borne Encephalitis and Omsk Hemorrhagic Fever. , 2011, , 515-518.		0
61	Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology, 2011, 409, 175-188.	1.1	85
62	Differential cytokine responses from primary human Kupffer cells following infection with wild-type or vaccine strain yellow fever virus. Virology, 2011, 412, 188-195.	1.1	21
63	T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture. Antimicrobial Agents and Chemotherapy, 2011, 55, 782-787.	1.4	94
64	Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses. Journal of Virology, 2011, 85, 10605-10616.	1.5	75
65	Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14926-14931.	3.3	47
66	Infection of hepatocytes with 17-D vaccine-strain yellow fever virus induces a strong pro-inflammatory host response. Journal of General Virology, 2011, 92, 2262-2271.	1.3	14
67	A proposal to change existing virus species names to non-Latinized binomials. Archives of Virology, 2010, 155, 1909-1919.	0.9	29
68	Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles. Journal of Virological Methods, 2010, 169, 259-268.	1.0	19
69	VIPR: a probabilistic algorithm for analysis of microbial detection microarrays. BMC Bioinformatics, 2010, 11, 384.	1.2	5
70	A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology, 2010, 397, 187-198.	1.1	67
71	Comparative analysis of immune responses to Russian springâ€“summer encephalitis and Omsk hemorrhagic fever viruses in mouse models. Virology, 2010, 408, 57-63.	1.1	19
72	Î³Î´ T cells promote the maturation of dendritic cells during West Nile virus infection. FEMS Immunology and Medical Microbiology, 2010, 59, 71-80.	2.7	51

#	Article	IF	Citations
73	Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. Journal of General Virology, 2010, 91, 765-772.	1.3	104
74	The NS5 Protein of the Virulent West Nile Virus NY99 Strain Is a Potent Antagonist of Type I Interferon-Mediated JAK-STAT Signaling. Journal of Virology, 2010, 84, 3503-3515.	1.5	189
75	Ubiquitin-Regulated Nuclear-Cytoplasmic Trafficking of the Nipah Virus Matrix Protein Is Important for Viral Budding. PLoS Pathogens, 2010, 6, e1001186.	2.1	110
76	Tick-Borne Flaviviruses. Clinics in Laboratory Medicine, 2010, 30, 221-235.	0.7	37
77	A broad-spectrum antiviral targeting entry of enveloped viruses. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3157-3162.	3.3	214
78	Tick-Borne Encephalitis. , 2009, , 713-734.		1
79	A Complex Adenovirus-Vectored Vaccine against Rift Valley Fever Virus Protects Mice against Lethal Infection in the Presence of Preexisting Vector Immunity. Vaccine Journal, 2009, 16, 1624-1632.	3.2	38
80	Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening. Drug Development Research, 2009, 70, 255-265.	1.4	33
81	Clinical evaluation of highly pathogenic tickâ€borne flavivirus infection in the mouse model. Journal of Medical Virology, 2009, 81, 1261-1269.	2.5	36
82	Sub-genomic replicon and virus-like particles of Omsk hemorrhagic fever virus. Archives of Virology, 2009, 154, 573-580.	0.9	16
83	A catalytically and genetically optimized Î²-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics. Virology Journal, 2009, 6, 119.	1.4	29
84	Single-particle cryo-electron microscopy of Rift Valley fever virus. Virology, 2009, 387, 11-15.	1.1	106
85	Potential Impact of a 2-Person Security Rule on BioSafety Level 4 Laboratory Workers. Emerging Infectious Diseases, 2009, 15, e1-e1.	2.0	5
86	Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology, 2008, 374, 198-209.	1.1	66
87	Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses. Antiviral Research, 2008, 78, 79-90.	1.9	77
88	Animal models of highly pathogenic RNA viral infections: Encephalitis viruses. Antiviral Research, 2008, 78, 69-78.	1.9	23
89	Phosphoinositide-3 Kinase-Akt Pathway Controls Cellular Entry of Ebola Virus. PLoS Pathogens, 2008, 4, e1000141.	2.1	168
90	Three-Dimensional Organization of Rift Valley Fever Virus Revealed by Cryoelectron Tomography. Journal of Virology, 2008, 82, 10341-10348.	1.5	110

#	Article	IF	Citations
91	Framework for Leadership and Training of Biosafety Level 4 Laboratory Workers. Emerging Infectious Diseases, 2008, 14, 1685-1688.	2.0	38
92	Structure of the envelope protein domain III of Omsk hemorrhagic fever virus. Virology, 2006, 351, 188-195.	1.1	17
93	An Animal Model for the Tickborne Flavivirusâ€"Omsk Hemorrhagic Fever Virus. Journal of Infectious Diseases, 2005, 191, 100-108.	1.9	57
94	Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology, 2005, 342, 167-176.	1.1	50
95	Solution Structure and Antibody Binding Studies of the Envelope Protein Domain III from the New York Strain of West Nile Virus. Journal of Biological Chemistry, 2004, 279, 38755-38761.	1.6	94
96	Use of a Recombinant Envelope Protein Subunit Antigen for Specific Serological Diagnosis of West Nile Virus Infection. Journal of Clinical Microbiology, 2004, 42, 2759-2765.	1.8	59
97	Molecular determinants of antigenicity of two subtypes of the tick-borne flavivirus Omsk haemorrhagic fever virus. Journal of General Virology, 2004, 85, 1619-1624.	1.3	18
98	Letter to the Editor:1H,13C and15N Resonance Assignments for Domain III of the West Nile Virus Envelope Protein. Journal of Biomolecular NMR, 2004, 29, 445-446.	1.6	2
99	Use of Recombinant E Protein Domain III-Based Enzyme-Linked Immunosorbent Assays for Differentiation of Tick-Borne Encephalitis Serocomplex Flaviviruses from Mosquito-Borne Flaviviruses. Journal of Clinical Microbiology, 2004, 42, 4101-4110.	1.8	54
100	Solution Structure and Structural Dynamics of Envelope Protein Domain III of Mosquito- and Tick-Borne Flavivirusesâ€. Biochemistry, 2004, 43, 9168-9176.	1.2	38
101	Analysis of the complete genome of the tick-borne flavivirus Omsk hemorrhagic fever virus. Virology, 2003, 313, 81-90.	1.1	44
102	Crystallization and preliminary X-ray diffraction analysis of Langat virus envelope protein domain III. Acta Crystallographica Section D: Biological Crystallography, 2003, 59, 1049-1051.	2.5	9
103	Nucleotide sequence and deduced amino acid sequence of the medium RNA segment of Oropouche, a Simbu serogroup virus: Comparison with the middle RNA of Bunyamwera and California serogroup viruses. Virus Research, 2001, 73, 153-162.	1.1	9
104	Nucleotide sequencing and serological evidence that the recently recognized deer tick virus is a genotype of Powassan virus. Virus Research, 2001, 79, 81-89.	1.1	55
105	Amino Acid Substitution(s) in the Stem-Anchor Region of Langat Virus Envelope Protein Attenuates Mouse Neurovirulence. Virology, 2001, 286, 54-61.	1.1	16
106	Langat Virus M Protein Is Structurally Homologous to prM. Journal of Virology, 2001, 75, 3999-4001.	1.5	6
107	Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity. Biochemical Journal, 2000, 352, 99.	1.7	7
108	The French neurotropic vaccine strain of yellow fever virus accumulates mutations slowly during passage in cell culture. Virus Research, 2000, 69, 31-39.	1.1	12

#	Article	IF	Citations
109	Epidermal Growth Factor Receptor Internalization Rate Is Regulated by Negative Charges near the SH2 Binding Site Tyr992â€. Biochemistry, 1999, 38, 9348-9356.	1.2	20